Entia Biosciences Inc (ERGO) financial statements (2021 and earlier)

Company profile

Business Address 13565 SW TUALATIN-SHERWOOD RD.
SHERWOOD, OR 97140
State of Incorp. NV
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments76218 2441182
Cash and cash equivalents76218 2441182
Receivables86101075348
Inventory, net of allowances, customer advances and progress billings7029133140118124
Inventory7029133140118124
Prepaid expense81364145571521
Total current assets:234738286128227375
Noncurrent Assets
Inventory, Noncurrent 35555555  
Property, plant and equipment18222529333639
Intangible assets, net (including goodwill)187236238236233345345
Intangible assets, net (excluding goodwill)187236238236233345345
Total noncurrent assets:205293318320320382384
TOTAL ASSETS:439366400406449609758
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,3601,4571,2991,071961762674
Accrued liabilities707759636455365355366
Employee-related liabilities     327321
Other undisclosed accounts payable and accrued liabilities65369866361659580(13)
Debt1327481979759
Deferred compensation liability (19)(30)(41)(52)(63)(73)
Due to related parties8101010 1413
Other undisclosed current liabilities605189132143234182218
Total current liabilities:2,1061,7111,4931,2801,240900841
Noncurrent Liabilities
Long-term debt and lease obligation276275273153   
Long-term debt, excluding current maturities276275273153   
Liabilities, other than long-term debt242424    
Due to related parties242424    
Total noncurrent liabilities:300299297153   
Total liabilities:2,4062,0091,7901,4321,240900841
Stockholders' equity
Stockholders' equity attributable to parent, including:(1,967)(1,644)(1,390)(1,027)(791)(291)(82)
Preferred stock0000000
Common stock28282828282927
Additional paid in capital12,48712,38712,36312,33612,30912,51612,370
Deferred compensation equity(9)      
Accumulated deficit(14,473)(14,040)(13,751)(13,350)(13,077)(12,774)(12,407)
Other undisclosed stockholders' equity attributable to parent (19)(30)(41)(52)(63)(73)
Total stockholders' equity:(1,967)(1,644)(1,390)(1,027)(791)(291)(82)
TOTAL LIABILITIES AND EQUITY:439366400406449609758

Income statement (P&L) ($ in thousands)

12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
Revenues464298796868108
Cost of revenue
(Cost of Goods and Services Sold)
(10)(13)(36)(32)(31)(22)(47)
Gross profit:36286347374661
Operating expenses(422)(300)(446)(317)(318)(380)(1,012)
Operating loss:(386)(271)(383)(270)(281)(334)(950)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(4)(3)(0)0(16)(32)(26)
Interest and debt expense(44)(15)(18)(3)(7)(1)(93)
Net loss available to common stockholders, diluted:(433)(289)(402)(273)(303)(367)(1,069)

Comprehensive Income ($ in thousands)

12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
Net loss:(433)(289)(402)(273)(303)(367)(1,069)
Comprehensive loss, net of tax, attributable to parent:(433)(289)(402)(273)(303)(367)(1,069)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: